<DOC>
	<DOCNO>NCT00745992</DOCNO>
	<brief_summary>Voriconazole effective antifungal agent may decrease morbidity mortality patient invasive fungal infection . It metabolize via liver enzyme . However , enzymes exhibit different activity individual patient ( genetic polymorphism ) . Higher proportion Asians metabolize voriconazole slow Caucasians African Americans . Slower metabolizers may experience dose-associated adverse event frequently , visual disturbance , liver function test abnormality , neurological complication . On hand , extensive metabolizer physiologic condition may lead low blood level voriconazole , may result treatment failure . We plan enroll patient take voriconazole examine liver enzyme activity blood sample peak trough drug level . We collect potential factor affect voriconazole level , correlate level dose regimen , activity liver enzyme , occurrence adverse event , treatment outcome . The goal study determine monitoring voriconazole blood level necessary Taiwan .</brief_summary>
	<brief_title>Voriconazole Blood Level Liver Metabolizing Enzyme Taiwanese Patients</brief_title>
	<detailed_description>The incidence opportunistic , invasive fungal infection dramatically increase past two decade cause high morbidity mortality variety patient population . Voriconazole , triazole antifungal agent , show vitro activity many yeast variety mold dermatophyte isolates . Voriconazole administer either orally parenterally . It exhibit good oral bioavailability wide tissue distribution . Voriconazole extensively metabolize hepatic cytochrome P450 isoenzymes , CYP 2C19 , CYP 2C9 CYP 3A4 . The affinity voriconazole great isoenzyme CYP 2C19 exhibit genetic polymorphism 15-20 % Asian population poor/slow metabolizers , whereas prevalence much low ( 3-5 % ) amongst Caucasians African Americans . Studies conduct Caucasian Japanese healthy subject demonstrate poor metabolizers , average , four time higher voriconazole AUC homozygous extensive metabolisers , AUC heterozygous extensive metabolizers two time higher homozygous extensive metabolizers . The commonly reported adverse event associate voriconazole use include visual disturbance , liver function test abnormality , neurological complication . All report associate high plasma concentration / dos . In term efficacy , analysis show trend toward bad outcome patient voriconazole plasma concentration &lt; 0.5 Î¼g/mL although remain controversial . Since Asians CYP 2C19 polymorphism , expect see patient wider range voriconazole plasma concentration previous study Caucasian patient . Our study likely provide strong evidence explanation relationship voriconazole plasma concentration clinical observation . We plan enroll patient take voriconazole examine CYP 2C19 genotype plasma sample peak trough concentration . We collect potential confounding factor affect voriconazole plasma concentration , correlate concentration dose regimen , presence absence CYP 2C19 polymorphism , occurrence adverse event , treatment outcome . The result study beneficial clarify international debate controversial issue voriconazole plasma concentration monitoring . The ultimate goal study determine monitoring voriconazole plasma concentration desire select patient population certain circumstance Taiwan .</detailed_description>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<criteria>Hospitalization patient ambulatory patient Patients invasive fungal infection Patients take PO/IV voriconazole 3 day</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Voriconazole</keyword>
	<keyword>Antifungal Agents</keyword>
	<keyword>Invasive fungal infection</keyword>
	<keyword>Therapeutic drug monitoring</keyword>
	<keyword>CYP Genetic polymorphism</keyword>
</DOC>